OBJECTIVE: To compare the long-term efficacy and safety of aripiprazole with olanzapine in patients with either acute relapsing or chronic, stable schizophrenia. MATERIALS AND METHODS: A 52-week, open-label extension to a 26-week, multicenter, randomized, double-blind, placebo-controlled trial in patients with chronic schizophrenia. Patients who completed the initial treatment or who met the protocol definition of relapse after > or =2 weeks of double-blind treatment were randomized to aripiprazole (15-30 mg/day, n = 104) or olanzapine (10-20 mg/day, n = 110) for 52 weeks. RESULTS:Sixty-nine percent of patients completed the study. Efficacy improvements were similar between groups at endpoint, mean reductions in Positive and Negative Syndrome Scale (PANSS) Total scores from baseline for patients completing the study (observed cases) were similar in chronic stable patients (aripiprazole, -7.94; olanzapine, -7.36) and in patients with acute relapse (aripiprazole, -31.19; olanzapine, -29.55). Olanzapine-treated patients reported more extrapyramidal symptoms (EPS)-related adverse events (18%) than aripiprazole-treated patients (10%). No significant differences in EPS were seen between treatments at endpoint. Olanzapine was associated with significantly greater weight gain than aripiprazole at all time points (week 52 [LOCF]: +2.54 vs +0.04 kg; p < 0.001). Changes in fasting glucose and lipid levels at endpoint favored aripiprazole over olanzapine, with significant differences observed for total cholesterol, low- and high-density lipoprotein. While differences observed for changes in fasting glucose and triglycerides favored aripiprazole, they were not statistically significant. CONCLUSION:Aripiprazole showed similar efficacy to olanzapine for long-term treatment of acutely psychotic and chronic, stable schizophrenia patients, with a lower liability for weight gain or increased lipid levels.
RCT Entities:
OBJECTIVE: To compare the long-term efficacy and safety of aripiprazole with olanzapine in patients with either acute relapsing or chronic, stable schizophrenia. MATERIALS AND METHODS: A 52-week, open-label extension to a 26-week, multicenter, randomized, double-blind, placebo-controlled trial in patients with chronic schizophrenia. Patients who completed the initial treatment or who met the protocol definition of relapse after > or =2 weeks of double-blind treatment were randomized to aripiprazole (15-30 mg/day, n = 104) or olanzapine (10-20 mg/day, n = 110) for 52 weeks. RESULTS: Sixty-nine percent of patients completed the study. Efficacy improvements were similar between groups at endpoint, mean reductions in Positive and Negative Syndrome Scale (PANSS) Total scores from baseline for patients completing the study (observed cases) were similar in chronic stable patients (aripiprazole, -7.94; olanzapine, -7.36) and in patients with acute relapse (aripiprazole, -31.19; olanzapine, -29.55). Olanzapine-treated patients reported more extrapyramidal symptoms (EPS)-related adverse events (18%) than aripiprazole-treated patients (10%). No significant differences in EPS were seen between treatments at endpoint. Olanzapine was associated with significantly greater weight gain than aripiprazole at all time points (week 52 [LOCF]: +2.54 vs +0.04 kg; p < 0.001). Changes in fasting glucose and lipid levels at endpoint favored aripiprazole over olanzapine, with significant differences observed for total cholesterol, low- and high-density lipoprotein. While differences observed for changes in fasting glucose and triglycerides favored aripiprazole, they were not statistically significant. CONCLUSION:Aripiprazole showed similar efficacy to olanzapine for long-term treatment of acutely psychotic and chronic, stable schizophreniapatients, with a lower liability for weight gain or increased lipid levels.
Authors: Stefan Leucht; Thomas R E Barnes; Werner Kissling; Rolf R Engel; Christoph Correll; John M Kane Journal: Am J Psychiatry Date: 2003-07 Impact factor: 18.112
Authors: Robert D McQuade; Elyse Stock; Ron Marcus; Darlene Jody; Neveen A Gharbia; Simon Vanveggel; Don Archibald; William H Carson Journal: J Clin Psychiatry Date: 2004 Impact factor: 4.384
Authors: Steven G Potkin; Anutosh R Saha; Mary J Kujawa; William H Carson; Mirza Ali; Elyse Stock; Joseph Stringfellow; Gary Ingenito; Stephen R Marder Journal: Arch Gen Psychiatry Date: 2003-07
Authors: Alexander L Miller; Catherine S Hall; Robert W Buchanan; Peter F Buckley; John A Chiles; Robert R Conley; M Lynn Crismon; Larry Ereshefsky; Susan M Essock; Molly Finnerty; Stephen R Marder; Del D Miller; Joseph P McEvoy; A John Rush; Sy A Saeed; Nina R Schooler; Steven P Shon; Scott Stroup; Bernardo Tarin-Godoy Journal: J Clin Psychiatry Date: 2004-04 Impact factor: 4.384
Authors: John M Kane; William H Carson; Anutosh R Saha; Robert D McQuade; Gary G Ingenito; Dan L Zimbroff; Mirza W Ali Journal: J Clin Psychiatry Date: 2002-09 Impact factor: 4.384
Authors: Siegfried Kasper; Mark N Lerman; Robert D McQuade; Anutosh Saha; William H Carson; Mirza Ali; Donald Archibald; Gary Ingenito; Ronald Marcus; Teresa Pigott Journal: Int J Neuropsychopharmacol Date: 2003-12 Impact factor: 5.176
Authors: Teresa A Pigott; William H Carson; Anutosh R Saha; Anne F Torbeyns; Elyse G Stock; Gary G Ingenito Journal: J Clin Psychiatry Date: 2003-09 Impact factor: 4.384
Authors: N A Muma; R K Singh; M S Vercillo; D N D'Souza; B Zemaitaitis; F Garcia; K J Damjanoska; Y Zhang; G Battaglia; L D Van de Kar Journal: Neuropharmacology Date: 2007-07-01 Impact factor: 5.250
Authors: Taishiro Kishimoto; Katsuhiko Hagi; Masahiro Nitta; John M Kane; Christoph U Correll Journal: World Psychiatry Date: 2019-06 Impact factor: 49.548
Authors: Jason G Ho; Randall L Caldwell; Christopher J McDougle; Danielle K Orsagh-Yentis; Craig A Erickson; David J Posey; Kimberly A Stigler Journal: J Child Adolesc Psychopharmacol Date: 2012-07-31 Impact factor: 2.576